Pharma giant Biogen Inc. (NASDAQ: BIIB) on Tuesday announced financial results for the third quarter of 2022, reporting a double-digit drop in
Infographic: Highlights from Biogen’s (BIIB) Q3 2022 earnings results
Categories
pharmaceuticals
Infographic: Highlights of Intuitive Surgical’s Q3 2022 earnings
Medical device company Intuitive Surgical, Inc. (NASDAQ: ISRG) said its third-quarter adjusted earnings remained unchanged year-over-year, while revenues increased in double digits.
Key highlights from Abbott (ABT) Q3 2022 earnings results
Abbott (NYSE: ABT) reported third quarter 2022 earnings results today. Sales decreased 4.7% year-over-year to $10.4 billion. On an organic basis, sales
JNJ Earnings: Johnson & Johnson Q3 adj. profit drops despite higher sales
Johnson & Johnson (NYSE: JNJ) reported a decline in adjusted profit for the third quarter of 2022, despite a modest increase in net
Johnson & Johnson (JNJ) offers long-term stability. Is the stock a buy?
Johnson & Johnson (NYSE: JNJ) has stayed largely unaffected by the COVID crisis and macroeconomic headwinds so far, which allowed the healthcare
TLRY Earnings: Highlights of Tilray’s Q1 2023 financial results
Cannabis company Tilray (NASDAQ: TLRY) has announced financial results for the first quarter of 2023, reporting a wider net loss and a
ANGO Earnings: AngioDynamics Q1 loss widens. Revenue up 6%
AngioDynamics Inc. (NASDAQ: ANGO) on Friday reported a wider loss for the first quarter of 2023, despite a modest increase in revenues.
Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know
After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered
Trxade Health Inc. (NASDAQ: MEDS) Q3 2022 Research Summary
Trxade Health Inc. (NASDAQ: MEDS) is an integrated drug delivery platform that offers a digitalized retail pharmacy experience to independent pharmacies, allowing
IPO Alert: Third Harmonic files to go public. Here’s what you need to know
IPO activity has started gaining steam after falling significantly in the first half, in line with the global trend, but it is
Pfizer (PFE): A look at the headwinds and tailwinds this pharma giant faces in the near term
Shares of Pfizer Inc. (NYSE: PFE) were down on Monday. The stock has dropped 15% year-to-date and there is a mixed sentiment
Trxade will focus more on core biz, connect with POS systems: CEO Suren Ajjarapu
Trxade Health Inc. (NASDAQ: MEDS) has been on a mission to digitalize the retail pharmacy experience by providing a platform for independent
Eli Lilly and Company (LLY) Earnings: 2Q22 Key Numbers
Eli Lilly and Company (NYSE: LLY) reported second quarter 2022 earnings results today. Worldwide revenue decreased 4% to $6.49 billion compared to the
CVS Health Corporation (CVS) Q2 2022 Earnings: Key financials and quarterly highlights
CVS Health Corporation (NYSE: CVS) reported second quarter 2022 earnings results today. Total revenues increased 11% year-over-year to $80.6 billion. Net income
ABBV Earnings: Highlights of AbbVie’s Q2 2022 financial results
Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) has reported double-digit growth in second-quarter adjusted earnings, reflecting an increase in revenues. The company also
Bristol Myers Squibb (BMY) Q2 2022 Earnings: Key financials and quarterly highlights
Bristol Myers Squibb (NYSE: BMY) reported second quarter 2022 earnings results today. Total revenue grew 2% year-over-year to $11.9 billion. Net earnings
Pfizer (PFE) Q2 2022 Earnings: Key financials and quarterly highlights
Pfizer Inc. (NYSE: PFE) reported second quarter 2022 earnings results today. Total revenues increased 47% year-over-year to $27.7 billion. Reported net income
MEDS Earnings: Trxade Health Q2 revenues surge 73% amid continued user growth
Trxade Health Inc (NASDAQ: MEDS), a leading health service IT company, reported a sharp increase in its second-quarter 2022 revenues. The top
Abbott Laboratories (ABT) Earnings: 2Q22 Key Numbers
Abbott Laboratories (NYSE: ABT) reported second quarter 2022 earnings results. Total sales increased 10.1% year-over-year to $11.3 billion. On an organic basis,
JNJ Earnings: Johnson & Johnson reports higher sales and adj. profit for Q2
Johnson & Johnson (NYSE: JNJ) reported an increase in sales and adjusted profit for the second quarter of 2022 when strong performance by
What awaits Johnson & Johnson (JNJ) beyond consumer business spinoff
Johnson & Johnson (NYSE: JNJ) is probably the most diversified healthcare firm that owns several popular consumer brands, which have brought both